Erratum: Substrate-based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase (Journal of Medicinal Chemistry (2013) 56 (7636?7650) DOI: 10.1021/jm401037h);Substrate-Based fragment identification for the development of selective, nonpeptidic inhibitors of striatal-enriched protein tyrosine phosphatase

Journal of Medicinal Chemistry

Volumn 56, Issue 19, 2013, Pages 7636-7650

  Baguley, Tyler D ^a   Xu, Hai Chao ^a,c   Chatterjee, Manavi ^a   Nairn, Angus C ^b   Lombroso, Paul J ^a   Ellman, Jonathan A ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE PHOSPHATASE INHIBITOR; STRIATAL ENRICHED PROTEIN TYROSINE PHOSPHATASE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; [DIFLUORO [2' (METHYLSULFONAMIDO) (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [2' HYDROXY (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [2' HYDROXY 3' ISOPROPYL (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [2' HYDROXY 5' ISOPROPYL (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [2' METHOXY (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [3' (1 HYDROXYETHYL) (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [3' (METHYLSULFONAMIDO) (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [3' (PHENYLAMINO) (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [3' ISOPROPOXY (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [3' ISOPROPYL (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [3' ISOPROPYL (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [3' METHYL (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [4' (1 HYDROXYETHYL) (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [4' ISOPROPOXY (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [4' ISOPROPYL (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [4' ISOPROPYL (1,1' BIPHENYL) 4 YL]METHYL]PHOSPHONIC ACID; [DIFLUORO [4' METHYL (1,1' BIPHENYL) 3 YL]METHYL]PHOSPHONIC ACID; [[2' CYANO (1,1' BIPHENYL) 4 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[3' (TERT BUTYL) 2' HYDROXY (1,1' BIPHENYL) 3 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[3' CYANO (1,1' BIPHENYL) 4 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[3' CYCLOBUTYL 2' HYDROXY (1,1' BIPHENYL) 3 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[3' CYCLOHEPTYL 2' HYDROXY (1,1' BIPHENYL) 3 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[3' CYCLOHEXYL 2' HYDROXY (1,1' BIPHENYL) 3 YL](HYDROXY)METHYL]PHOSPHONIC ACID; [[3' CYCLOHEXYL 2' HYDROXY (1,1' BIPHENYL) 3 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[3' CYCLOPENTYL 2' HYDROXY (1,1' BIPHENYL) 3 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[3' ETHYL 2' HYDROXY (1,1' BIPHENYL) 3 YL]DIFLUOROMETHYL]PHOSPHONIC ACID; [[4' CYANO (1,1' BIPHENYL) 4 YL]DIFLUOROMETHYL]PHOSPHONIC ACID;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CELL; BROMINATION; CELL CULTURE; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; MOLECULAR WEIGHT; NONHUMAN; RAT; STEREOISOMERISM; SUBSTITUTION REACTION; SUZUKI REACTION;

EID: 84885665185     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm5018847     Document Type: Erratum

References (55)

1. Lüscher, C.; Issac, J. T. The synapse: center stage for many brain diseases J. Physiol. 2009, 587, 727-729
2. Palop, J. J.; Chin, J.; Mucke, L. A network dysfunction perspective on neurodegenerative diseases Nature 2006, 443, 768-773
3. Selkoe, D. J. Alzheimer's disease is a synaptic failure Science 2002, 298, 789-791
4. Burke, S. N.; Barnes, C. A. Neural plasticity in the ageing brain Nat. Rev. Neurosci. 2006, 7, 30-40
5. Stephan, K. E.; Friston, K. J.; Frith, C. D. Dysconnection in schizophrenia: from abnormal synaptic plasticity to failures of self-monitoring Schizophren. Bull. 2009, 35, 509-527
6. Stephan, K. E.; Baldeweg, T.; Friston, K. J. Synaptic plasticity and dysconnection in Schizophrenia Biol. Psychiatry 2006, 59, 929-939
7. Duman, R. S. Pathophysiology of depression: the concept of synaptic plasticity Eur. Psychiatry 2002, 17, 306-310
8. Garner, C. C.; Wetmore, D. Z. Synaptic pathology of Down syndrome Adv. Exp. Med. Biol. 2012, 970, 451-68
9. Huttenlocher, P. R. Dendritic and synaptic pathology in mental retardation Pediatr. Neurol. 1991, 7, 79-85
10. O'Donnell, W. T.; Warren, S. T. A decade of molecular studies of fragile X syndrome Annu. Rev. Neurosci. 2002, 25, 315-338
11. Gerdeman, G. L.; Partridge, J. G.; Lupica, C. R.; Lovinger, D. M. It could be habit forming: drugs of abuse and striatal synaptic plasticity Trends Neurosci. 2003, 26, 184-192
12. Paul, S.; Nairn, A.; Wang, P.; Lombroso, P. J. NMDA-mediated activation of the protein tyrosine phosphatase, STEP, regulates the duration of ERK signaling Nat. Neurosci. 2003, 6, 34-42
13. Xu, J.; Kurup, P.; Bartos, J. A.; Hell, J. W.; Lombroso, P. J. Striatal-enriched protein tyrosine phosphatase (STEP) regulates Pyk2 activity J. Biol. Chem. 2012, 287, 20942-20956
14. Munoz, J. J.; Tarrega, C.; BlancoAparicio, C.; Pulido, R. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38α is determined by a kinase specificity sequence and influenced by reducing agents Biochem. J. 2003, 372, 193-201
15. Snyder, E. M.; Nong, Y.; Almeida, C. G.; Paul, S.; Moran, T.; Choi, E. Y.; Nairn, A. C.; Salter, M. W.; Lombroso, P. J.; Gouras, G. K.; Greengard, P. Regulation of NMDA receptor trafficking by amyloid-β Nat. Neurosci. 2005, 8, 1051-1058
16. Zhang, Y. F.; Kurup, P.; Xu, J.; Carty, N.; Fernandez, S.; Nygaard, H. B.; Pittenger, C.; Greengard, P.; Strittmatter, S.; Nairn, A. C.; Lombroso, P. J. Genetic reduction of the tyrosine phosphatase STEP reverses cognitive and cellular deficits in a mouse model of Alzheimer's disease Proc. Nat. Acad. Sci. U.S.A. 2010, 107, 19014-19019
17. Zhang, Y. F.; Kurup, P.; Xu, J.; Anderson, G.; Greengard, P.; Nairn, A. C.; Lombroso, P. J. Reduced levels of the tyrosine phosphatase STEP block beta amyloid-mediated GluA1/GluA2 receptor internalization J. Neurochem. 2011, 119, 664-672
18. Soellner, M. B.; Rawls, K. A.; Grundner, C.; Alber, T.; Ellman, J. A. Fragment-based substrate activity screening method for the identification of potent inhibitors of the Mycobacterium tuberculosis phosphatase PtpB J. Am. Chem. Soc. 2007, 129, 9613-9615
19. Rawls, K. A.; Lang, P. T.; Takeuchi, J.; Imamura, S.; Baguley, T. D.; Grundner, C.; Alber, T.; Ellman, J. A. Fragment-based discovery of selective inhibitors of the Mycobacterium tuberculosis protein tyrosine phosphatse PtpA Bioorg. Med. Chem. Lett. 2009, 19, 6851-6854
20. Sahn, J. J.; Martin, S. F. Expedient synthesis of norbenzomorphan library via multicomponent assembly process coupled with ring-closing reactions ACS Comb. Sci. 2012, 14, 496-502
21. For a discussion of the high incidence of false positives in phosphatase screening, see the following: Moretto, A. F.; Kirincich, S. J.; Xu, W. X.; Smith, M. J.; Wan, Z. K.; Wilson, D. P.; Follows, B. C.; Binnun, E.; Joseph-McCarthy, D.; Foreman, K.; Erbe, D. V.; Zhang, Y. L.; Tam, S. K.; Tam, S. Y.; Lee, J. Bicyclic and tricyclic thiophenes as protein tyrosine phosphatase 1B inhibitors Bioorg. Med. Chem. 2006, 14, 2162-2177
22. Vintonyak, V. V.; Waldmann, H.; Rauh, D. Inhibitors of protein tyrosine phosphatases: next-generation drugs? Bioorg. Med. Chem. 2011, 19, 2145-2155
23. Combs, A. P. Recent advances in the discovery of competitive protein tyrosine phosphatase 1B inhibitors for the treatment of diabetes, obesity, and cancer J. Med. Chem. 2010, 53, 2333-2344
24. Blaskovich, M. A. T. Drug discovery and protein tyrosine phosphatases Curr. Med. Chem. 2009, 16, 2095-2176
25. Hajduk, P. J.; Bures, M.; Praesstgaard, J.; Fesik, S. W. Privileged molecules for protein binding identified from NMR-based screening J. Med. Chem. 2000, 43, 3443-3447
26. Horton, D. A.; Bourne, G. T.; Smythe, M. L. The combinatorial synthesis of bicyclic privileged structures or privileged substructures Chem. Rev. 2003, 103, 893-930
27. 2Pmp Biochem. Biophys. Res. Commun. 1994, 204, 129-134
28. Montalibet, J.; Skorey, K. I.; Kennedy, B. P. Protein tyrosine phosphatase: enzymatic assays Methods 2005, 35, 2-8
29. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening J. Med. Chem. 2002, 45, 1712-1722
30. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition J. Med. Chem. 2003, 46, 4265-4272
31. Shoichet, B. K. Screening in a spirit haunted world Drug Discovery Today 2006, 11, 607-615
32. Murano, T.; Takechi, H.; Yuasa, Y.; Yokomatsu, T.; Umesue, I.; Soeda, S.; Shimeno, H.; Shibuya, S. The difluoromethylenephosphonothioic acid group as a phosphate surrogate for obtaining PTP-1B inhibitors. Transformation of difluoromethyenephosphonic acids into difluoromethylenephosphonothioic acids ARKIVOC 2003, 8, 256-266
33. Montserat, J.; Chen, L.; Lawrence, D. S.; Zhang, Z.-Y. Potent low molecular weight substrates for protein-tyrosine phosphatase J. Biol. Chem. 1996, 271, 7868-7872
34. Bahta, M.; Lountos, G. T.; Dyas, B.; Kim, S.-E.; Ulrich, R. G.; Waugh, D. S.; Burke, T. R., Jr. Utilization of nitrophenylphosphates and oxime-based ligation for the development of nanomolar affinity inhibitors of the Yersinia pestis outer protein H (YopH) phosphatase J. Med. Chem. 2011, 54, 2933-2943
35. Chen, L.; Montserat, J.; Lawrence, D. S.; Zhang, Z.-Y. VHR and PTP1 protein phosphatases exhibit remarkably different active site specificities toward low molecular weight nonpeptidic substrates Biochemistry 1996, 35, 9349-9354
36. Di, L.; Kerns, E. H.; Bezar, I. F.; Petusky, S. L.; Huang, Y. Comparison of blood-brain barrier permeability assays: in situ brain perfusion, MDR1-MDKII and PAMPA-BBB J. Pharm. Sci. 2009, 98, 1980-1991
37. Mensch, J.; Melis, A.; Mackie, C.; Verreck, G.; Brewster, M. E.; Augustijns, P. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability Eur. J. Pharm. Biopharm. 2010, 74, 495-502
38. Rautio, J.; Laine, K.; Gynther, M.; Savolainen, J. Prodrug Approaches for CNS Delivery AAPS J. 2008, 10, 92-102
39. Pavan, B.; Dalpiaz, A.; Ciliberti, N.; Biondi, C.; Manfredini, S.; Vertuani, S. Progress in drug discovery to the central nervous system by the prodrug approach Molecules 2008, 13, 1035-1065
40. Prokai, L.; Prokai-Tatrai, K.; Bodor, N. Targeting drugs to the brain by redox chemical delivery systems Med. Res. Rev. 2000, 20, 367-416
41. Fujisaki, S.; Eguchi, H.; Omura, A.; Okamato, A.; Nishida, A. Halogenation using N -halogenocompounds. I. Effect of amines on ortho-bromination of phenols with NBS Bull. Chem. Soc. Jpn. 1993, 66, 1576-1579
42. Konakahara, T.; Kiran, Y. B.; Okuno, Y.; Ikeda, R.; Sakai, N. An expedient synthesis of ellipticine via Suzuki-Miyaura coupling Tetrahedron Lett. 2010, 51, 2335-2338
43. Boebel, T. A.; Hartwig, J. F. Silyl-directed, iridium-catalyzed ortho-borylation of arenes. A one-pot ortho-borylation of phenols, arylamines, and alkylarenes J. Am. Chem. Soc. 2008, 130, 7534-7535
44. Ishiyama, T.; Murata, M.; Miyaura, N. Palladium(0)-catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: a direct procedure for arylboronic esters J. Org. Chem. 1995, 60, 7508-7510
45. Vedso, P.; Olesen, P. H.; Hoeg-Jensen, T. Synthesis of sulfonyl chlorides of phenyl-boronic acids Synlett 2004, 5, 892-894
46. Li, X.; Szardenings, A. K.; Holmes, C. P.; Wang, L.; Bhandari, A.; Shi, L.; Navre, M.; Jang, L.; Grove, J. R. A new and direct approach to functionalized biaryl α-ketophosphonic acids via aqueous Suzuki coupling on solid support Tetrahedron Lett. 2006, 47, 19-22
47. Kolodiazhnyi, O. I.; Grishkun, E. V.; Sheiko, S.; Demchuk, O.; Thoennessen, H.; Jones, P.; Schmutzler, R. Asymmetric synthesis of α-substituted alkylphosphonates based on symmetrical dialkyl phosphites Russ. Chem. Bull. 1999, 48, 1568-1573
48. 3-symmetric trialkyl phosphites as starting compounds of asymmetric synthesis Heteroat. Chem. 2000, 11, 138-143
49. Blazis, V. J.; Koeller, K. J.; Spilling, C. D. Reactions of chiral phosphorous acid diamides: the asymmetric synthesis of chiral α-hydroxy phosphonamides, phosphonates, and phosphonic acids J. Org. Chem. 1995, 60, 931-940
50. Smaardijk, A. A.; Noorda, S.; Van Bolhuis, F.; Wynberg, H. The absolute configuration of α-hydroxyphosphonates Tetrahedron Lett. 1985, 26, 493-496
51. Salvi, L.; Kim, J. G.; Walsh, P. J. Practical catalytic asymmetric synthesis of diaryl-, aryl heteroaryl-, and diheteroarylmethanols J. Am. Chem. Soc. 2009, 131, 12483-12493
52. Nugent, W. A. MIB: an advantageous alternative to DAIB for the addition of organozinc reagents to aldehydes Chem. Commun. 1999, 1369-1370
53. Ishiyama, T.; Murata, M.; Miyaura, N. Palladium(0)-catalyzed cross-coupling reaction of alkoxydiboron with haloarenes: a direct procedure for arylboronic esters J. Org. Chem. 1995, 60, 7508-7510
54. Xu, J.; Kurup, P.; Zhang, Y. F.; Goebel-Goody, S.; Wu, P.; Hawasli, A. H.; Baum, M.; Bibb, J.; Lombroso, P. J. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP J. Neurosci. 2009, 29, 9330-9343
55. Li, X.; Szardenings, A. K.; Holmes, C. P.; Wang, L.; Bhandari, A.; Shi, L.; Navre, M.; Jang, L.; Grove, J. R. A new and direct approach to functionalized biaryl α-ketophosphonic acids via aqueous Suzuki coupling on solid support Tetrahedron Lett. 2006, 47, 19-22